Scarica l'app Stockscreener
4.97
0.00%
0.00
Dopo l'orario di chiusura:
4.97
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BLUE Giù?
Forum
Previsione
Precedente Chiudi:
$4.97
Aprire:
$4.97
Volume 24 ore:
583.63K
Relative Volume:
1.00
Capitalizzazione di mercato:
$48.66M
Reddito:
$21.73M
Utile/perdita netta:
$-91.17M
Rapporto P/E:
-6.7162
EPS:
-0.74
Flusso di cassa netto:
$-286.43M
1 W Prestazione:
+42.00%
1M Prestazione:
+19.76%
6M Prestazione:
-22.54%
1 anno Prestazione:
-76.33%
Intervallo 1D:
$4.97
$4.99
Intervallo di 1 settimana:
$3.20
$4.99
Portata 52W:
$3.20
$28.60
Bluebird Bio Inc Stock (BLUE) Company Profile
Nome
Bluebird Bio Inc
Settore
Industria
Telefono
339-499-9300
Indirizzo
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Confronta BLUE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
4.97 | 34.27M | 21.73M | -91.17M | -286.43M | -0.74 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-24 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-11-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-08-15 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-12-11 | Downgrade | HSBC Securities | Hold → Reduce |
| 2023-12-08 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-17 | Iniziato | Cantor Fitzgerald | Neutral |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-19 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-06-01 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-04-28 | Iniziato | JP Morgan | Overweight |
| 2023-03-07 | Iniziato | Robert W. Baird | Outperform |
| 2022-08-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-08-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-04-06 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-07 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-11-08 | Reiterato | Barclays | Equal Weight |
| 2021-11-08 | Reiterato | Canaccord Genuity | Hold |
| 2021-11-08 | Downgrade | Goldman | Neutral → Sell |
| 2021-11-08 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-11-08 | Reiterato | Wedbush | Neutral |
| 2021-11-08 | Reiterato | Wells Fargo | Equal Weight |
| 2021-08-10 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-08-10 | Downgrade | Goldman | Buy → Neutral |
| 2021-08-10 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2021-08-10 | Ripresa | William Blair | Mkt Perform |
| 2021-08-09 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-01 | Downgrade | Berenberg | Buy → Hold |
| 2021-03-10 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-02-17 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-02-16 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-02-16 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-02-16 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-12-09 | Downgrade | Maxim Group | Buy → Hold |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-05 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-11-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-11-05 | Downgrade | Stifel | Buy → Hold |
| 2020-11-02 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2020-10-20 | Iniziato | Mizuho | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-27 | Aggiornamento | Stifel | Hold → Buy |
| 2020-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-02-03 | Ripresa | BofA/Merrill | Buy |
| 2020-02-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-12-13 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-11-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-11-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-04 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-10-01 | Iniziato | Stifel | Hold |
| 2019-08-12 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2019-06-18 | Aggiornamento | Maxim Group | Hold → Buy |
Mostra tutto
Bluebird Bio Inc Borsa (BLUE) Ultime notizie
Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions - BioSpace
Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions | BLUE Stock News - GuruFocus
Carlyle, SK Capital Partners And Bluebird Bio Provide Updated Tender Instructions - marketscreener.com
Beta thalassemia Market: Epidemiology, Therapies, Companies, - openPR.com
Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates - MSN
bluebird bio updates terms of Carlyle, SK Capital buyout By Investing.com - Investing.com Canada
Carlyle and SK Capital boost Bluebird Bio bid, offering flexible payout terms - Private Equity Insights
Bluebird: Q1 Earnings Snapshot - New Haven Register
Carlyle Group, SK Capital secure all regulatory approvals to acquire bluebird bio - MSN
Bluebird Bio (BLUE) Surges on Amended Deal with Carlyle and SK C - GuruFocus
bluebird bio, Inc. SEC 10-Q Report - TradingView
Bluebird, Private Equity Firms Look To Sweeten Buyout Deal - insights.citeline.com
Bluebird Bio Shareholders Get New All-Cash Offer From Private Equity - Yahoo Finance
bluebird bio shares soar after amended buyout offer from Carlyle, SK Capital - Proactive Investors
Bluebird Bio Stock Skyrockets on Revamped Buyout Offer - RagingBull
SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M - Endpoints News
Bluebird Bio's Acquisition Deal Offers Shareholders New Cash Option - Finimize
Bluebird bio investor reluctance pays off as Carlyle, SK improve buyout offer by 67% - Fierce Pharma
Bluebird Bio Stock Soars On Higher Upfront Payment Under Amended Merger Deal: Retail Gets More Bullish - MSN
Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital - Reuters
Bluebird bio soars on amended deal with Carlyle, SK Capital - MSN
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agree - GuruFocus
Bluebird Bio (BLUE) Amends Deal with SK Capital for Shareholder Options | BLUE Stock News - GuruFocus
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement - BioSpace
Bluebird Bio Takeover Bid: Shareholder Decision on $5 Per Share OfferNews and Statistics - IndexBox
Bluebird bio soars on amended deal with Carlyle, SK Capital (BLUE:NASDAQ) - Seeking Alpha
Bluebird Bio Amends Merger Agreement with Carlyle - TipRanks
bluebird bio stock soars 50% on improved buyout offer By Investing.com - Investing.com South Africa
bluebird bio stock soars 50% on improved buyout offer - Investing.com
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement | BLUE Stock News - GuruFocus
bluebird bio updates terms of Carlyle, SK Capital buyout - Investing.com
Bluebird bio warns of potential bankruptcy as buyout faces another delay - Fierce Pharma
Bluebird bio, Inc.(NasdaqGS: BLUE) dropped from S&P TMI Index - marketscreener.com
Bluebird bio, Inc.(NasdaqGS: BLUE) dropped from S&P Global BMI Index - marketscreener.com
Important Information for bluebird bio Stockholders to Tender Sh - GuruFocus
Gene Therapy Market Set for Strong Growth with Ongoing Rare - openPR.com
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital | BLUE Stock News - GuruFocus
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital - Yahoo Finance
Learn to Evaluate (BLUE) using the Charts - news.stocktradersdaily.com
bluebird bio, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your RightsBLUE - ACCESS Newswire
bluebird bio, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before May 28, 2024 to Discuss Your RightsBLUE - ACCESS Newswire
Shareholders that lost money on bluebird bio, Inc. (BLUE) should contact Levi & Korsinsky about pending Class ActionBLUE - ACCESS Newswire
Shareholders that lost money on bluebird bio, Inc. (BLUE) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
BLUE LAWSUIT ALERT: Levi & Korsinsky Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – BLUE - ACCESS Newswire
Investors in bluebird bio, Inc. Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights – BLUE - ACCESS Newswire
DEADLINE ALERT: Bernstein Liebhard LLP Reminds bluebird bio, Inc. Investors of Upcoming Deadline - ACCESS Newswire
Bluebird bio, Carlyle-SK Deal Clears Regulatory Hurdles - marketscreener.com
Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio - BioSpace
Bluebird Bio Inc Azioni (BLUE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):